Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Debt / NOTE 2.000% 8/1
-
Market price (% of par)
-
79.72%
-
Total 13F principal
-
$228,435,000
-
Principal change
-
+$1,951,600
-
Total reported market value
-
$183,797,000
-
Number of holders
-
16
-
Value change
-
+$1,680,496
-
Number of buys
-
3
-
Number of sells
-
8
Institutional Holders of AEGERION PHARMACEUTICALS INC - NOTE 2.000% 8/1 as of Q3 2017
As of 30 Sep 2017,
AEGERION PHARMACEUTICALS INC - NOTE 2.000% 8/1 was held by
16 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$228,435,000
in principal (par value) of the bond.
The largest 10 bondholders included
EdgePoint Investment Group Inc., HIGHBRIDGE CAPITAL MANAGEMENT LLC, Allianz Asset Management GmbH, UBS OCONNOR LLC, DEERFIELD MANAGEMENT CO, ORBIMED ADVISORS LLC, Tekla Capital Management LLC, AMERIPRISE FINANCIAL INC, BAKER BROS. ADVISORS LP, and Invesco Ltd..
This page lists
16
institutional bondholders reporting positions
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.